Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs . Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population
Anticancer Research · 2023
DOI: 10.21873/anticanres.16320 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Anticancer Research, 2023. Verfasst von Lola Macia-Rivas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Universidad de Santiago de Compostela, A Coruña, Spain; lolamaciarivas@gmail.com. Hauptthemen laut MEDLINE: Nivolumab, Head and Neck Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: This study aimed to assess the effectiveness and safety of nivolumab versus cetuximab in patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC), as well as to analyze possible prognostic factors for response to treatment with nivolumab. PATIENTS AND METHODS: We conducted an observational, retrospective, descriptive study of patients with R/M HNSCC who initiated treatment with nivolumab or cetuximab monotherapy in two periods of equivalent duration. Overall efficacy was measured in terms of progression-free survival (PFS) and overall survival (OS). Safety was evaluated using the Common Terminology Criteria for Adverse Events classification version 5.0 of the National Cancer Institute. RESULTS: Median OS was 9.1 months with nivolumab (n=34) and 6.3 months with cetuximab (n=12). PFS was 4.3 months for nivolumab and 4.65 months for cetuximab. Any grade adverse events (AEs) were reported in 97% and 100% of the patients treated with nivolumab and cetuximab. Serious AEs were observed in 26% and 58% of the patients, respectively. Elevated albumin values, lymphocytosis, neutropenia, and elevated neutrophil/lymphocyte ratio values were found to have positive prognostic value on the response to nivolumab in R/M HNSCC. CONCLUSION: Effectiveness of nivolumab in terms of OS remains superior to cetuximab. OS, PFS and severe or any grade AEs were superior in both arms of our study compared to those in clinical trials. The AEs profile of nivolumab differed in our study from that in the clinical trials' observations. We have identified four statistically significant prognostic variables on the response to nivolumab in R/M HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Universidad de Santiago de Compostela, A Coruña, Spain; lolamaciarivas@gmail.com.
- Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
ORCID-Profile: Lola Macia-Rivas
Zitieren
APA
Macia-Rivas, L., Fernandez-Laguna, C. L., Alvarez-Asteinza, C., Maray, I., Carbajales-Alvarez, M., & Lozano-Blazquez, A. (2023). Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs . Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population. Anticancer Research. https://doi.org/10.21873/anticanres.16320
Vancouver
Macia-Rivas L, Fernandez-Laguna CL, Alvarez-Asteinza C, Maray I, Carbajales-Alvarez M, Lozano-Blazquez A. Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs . Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population. Anticancer Research. 2023. doi:10.21873/anticanres.16320
BibTeX
@article{MaciaRivas2023,
author = {Macia-Rivas, Lola and Fernandez-Laguna, Clara Luz and Alvarez-Asteinza, Cristina and Maray, Ivan and Carbajales-Alvarez, Monica and Lozano-Blazquez, Ana},
title = {Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs . Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16320}
}
EUVIMED